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Introductory Chapter: From 
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The living animals and human organisms, organs, and cells are in a good equilib-
rium under the normal conditions. This excellent equilibrium can be kept with a 
lot of regulatory mechanisms at the level of whole organisms, different organs, 
and different cells, which together can organize the different regulatory steps and 
pathways under normal conditions for the living organisms. These regulatory 
mechanism systems represent a wonderful world. That is the very simple explana-
tion for that why many people do research works in these fields and they wanted 
to know more and more details about this wonderful world. The researchers are 
working in very different fields; however, all of us want to know more and more the 
essential and general laws of the different regulatory mechanism systems in hoping 
that these new observations will help us in keeping further this wonderful world in 
the forthcoming future.
The researcher people are biologists, bacteriologists, animal researchers, veteri-
nary physicians, human physicians (and related specialists, like anatomists, physi-
ologists, biochemists, pathologists, pharmacologists, basic researchers, clinicians, 
etc.), agricultural researchers, etc.
Basically we want to know more and more on the functions of living organisms; 
however, the possible approaching pathways are very different in the science; fur-
thermore the “science” is a permanently changed process. Firstly, we try to register 
the reactions (answers) of the whole organism, including physical, physiological, 
and psychological aspects. In other words, we will see the whole organisms at the 
first time; however, later we want to know more on their mechanisms involved in 
the different “whole” reactions. Consequently, the main research tendency turned 
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into the microworlds from the whole organisms (e.g., biochemistry, pharmacology, 
etc.), and now we are at the levels just at the level a small particles of cells (like 
different enzymes, biochemical reactions, membrane functions, nucleic acids, and 
very special particles).
This book contains four (five) different excellent chapters, three of them on 
theories of health and diseases and one more chapter dealing with human clinical 
problems, which together give a nice overview on the theories of human medical 
practical problem.
2. First and second messenger systems
The centrally and peripherally originated neural influences (mediators), differ-
ent hormones, and—during the medical treatments—different drugs reach in the 
serum the plasma cell membranes.
The terminology of cell membrane represents a very complicated system by 
using this terminology. A lot of different enzymes and receptors are located in the 
membranes with significantly different mechanisms (functions).
The different first messengers (hormones, mediators, drugs)—if they will not 
be inactivated in the serum—will meet first with the cell membrane, and they will 
modify the regulatory mechanisms in different extents.
The so-called sodium pump has been studied widely in the physiology. This 
“sodium pump” system was responsible for the keeping of equilibrium between the 
significant concentration gradients of sodium and potassium in the serum versus 
intracellularly.
There was no question that this process is an energy-dependent process; how-
ever, the details were not known.
The sodium-potassium pump was discovered by Skou (in Denmark) in the 
1950s, and it was proved that this sodium-potassium pump is responsible for the 
so-called sodium pump (1965). The sodium-potassium pump can be worked by a 
membrane enzyme. This enzyme is located in the membrane, splitted the mito-
chondrial adenosine triphosphate (ATP) and presence of Mg2+, Na+ and K+, and this 
process can be inhibited by application of g strophantin (ouabain). Skou (Aarhus, 
Denmark) was awarded the Nobel Prize of Chemistry in 1997.
Later Sutherland (who received the Nobel Prize of Physiology or Medicine in 
2001) discovered the existence of adenylate cyclase enzyme. This enzyme is also 
located in the cell membrane, and the same electrolytes are necessary for the func-
tion as in the case of membrane ATPase.
Consequently, it became clear that the mitochondrial adenosine triphosphate is a 
common substrate for both membrane ATPase and adenylate cyclase.
The breakdown of mitochondrial ATP by membrane ATPase is adenosine 
diphosphate, while adenylate cyclase is cyclic adenosine monophosphate (cAMP). 
During these processes, energy will be liberated in the cells; however their extents 
are different from each other, namely, its value is about two times higher in the case 
of adenylate cyclase than in the case of membrane ATPase. The adenosine mono-
phosphate is a common split intracellular compound after the breakdown of ADP 
and cAMP.
Atkinson (1968) created a formula to express the values of the actual tissue 
circumstances of phosphorylation/dephosphorylation by the following method: 
[(ATP + O.5 ADP)/(ATP + ADP + AMP)]. This value is equal to l, when all adenos-
ine compounds are in the phosphorylate form, and this value is zero, when all 
adenosine compounds are in the dephosphorylated form. The application of this 
formula is very useful in different observation circumstances.
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From these very short informations, our attention has been focused in our peptic 
ulcer research.
The second messenger systems are very complicated in our days, which are out 
of our present work.
The editor of this book is a physician (internist, gastroenterologist, clinical 
pharmacologist). However, before the editor would turn in the clinical works, he 
worked a cup of years in physiological and pharmacological (molecular and bio-
chemical pharmacological) departments. When I met—as a physician—with the 
patients, I registered many difficulties in their everyday medical duties, namely, the 
patient’s treatments, and before taking of good diagnoses.
3. Molecular biochemical observations in human peptic ulcer diseases
My clinical work started in a medical department at Second Department of 
Medicine, University of Debrecen, Hungary (1960). I met with a lot of gastroen-
terological patients, who originally suffered from “classic or genuine” peptic ulcer 
disease (PUD) (with and without gastrointestinal (GI) bleedings). We had very 
limited possibilities to take diagnosis (PUD) and treatments of patients with PUD 
in the 1960s; however, in the forthcoming 10 years, the fiberoscopes appeared, 
beside the X-ray examinations. The etiological role of tissue hypoxia was suggested 
in the development of gastroduodenal mucosal damage in association with the 
increased tone (activity) of the vagus nerve. In the different European countries, 
the patients received atropine treatment (three times/day in doses of 0.3–0.9 orally 
or 0.5–1.0 mg intramuscularly for 3–4 weeks). The scopolamine was used in the 
USA beside the atropine. Following the medical treatment, we believed that the 
patients healed, or we (internists) offered further the patient to surgeons for taking 
gastric surgery (partial gastrectomy or partly surgical vagotomy).
The increased gastric secretory acid secretion was believed to be in the back-
ground of PUD; however no objective method(s) was (were) in the hand of 
clinicians to measure the quantities of gastric acid secretion at that time. In the 
1960s—near their end—different methods were established to measure gastric acid 
secretion (including the gastric basal acid outputs, BAO, and maximal acid output, 
MAO) using nasogastric tubes, and patients were given different doses of histamine 
or pentagastrin. Independently from the presence of these methods, practically 
these were not used generally in the everyday medical practice.
Many things (methods of clinical observations, modern endoscopic instru-
ments) changed in the forthcoming time, and the basic pharmacological research 
produced a lot of tertiary and quaternary ammonium components (as antisecretory 
agents). The effects of these compounds were tested practically in animal observa-
tions, and these results were accepted by the clinicians and introduced into the 
medical treatment. The results differed in patients from those obtained in animal 
experiments, and in some cases no beneficial effect of used drug is obtained in 
patients. Between the years 1960 and 1970, a modern methodology was elaborated 
by us to objectively measure drug absorption, metabolism, excretion, serum levels 
of applied drugs, gastric acid secretory responses (BAO, MAO), parotid secretory 
responses, gastric motility, and gastric emptying. These results obtained in oral or 
parenteral application of different drugs offered a possibility to establish a complex 
clinical pharmacological methodology for parasympatholytics and for other drugs.
The human clinical pharmacology developed further as produced the necessary 
the controlled clinical pharmacological trials of different drugs. The first step was 
to prove that really the different drugs have any beneficial effect of the target organ. 
The identification and determination of drug action (“without giving any active 
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drugs”) were one of the biggest problems (placebo effect) of the human medical 
therapy (some to up to now, the correct understanding of this problems represents 
an essential scientific and medical treatment problems) (like production of new 
potentially new molecule is the research medicine, and the same in the clinical 
practice). This problem is now out of our point of view in the practical every day 
medical treatments.
We had good opportunity to carry out enough human studies on PUD patients 
with different parasympatholytics, histamine H2 receptor blockings, antigastrin, 
and proton pump inhibitors (PPI), antioxidants, and scavengers (so-called cytopro-
tective agents, like vitamin A, beta-carotene).
Just a small explanation is needed to understand the following step in our 
research. The vitamin A and beta-carotene are both together, and these agents are 
essential participants of human nutrition; however, these compounds have no any 
inhibitory effect on the human (and animal) gastric acid secretion. These observa-
tions excluded, at least in some part, that only the gastric acid (HCl) secretion is a 
responsible etiological factor to the development of GI ulcer diseases. Our clinical 
pharmacological studies clearly indicated existence of this phenomenon of this 
factor in patients with duodenal and gastric peptic ulcer. It was also very surprising 
when we carried out regular treatment with atropine in duodenal ulcer patients, 
we found that the ulcers healed; however the gastric acid secretion did not change 
during the chronic treatment [1]; meanwhile the terminology of “cytoprotection” 
was introduced by André Robert et al. in 1979, and later this name was generally 
accepted worldwide.
Originally, we wanted to understand the etiological background of PUD and the 
details of our medical activities during the patients’ treatments. We tried to analyze 
very carefully the many results of correct human pharmacological treatments, 
and we were not able to understand the “essential point(s)” of etiology of PUD 
and our treatments. Furthermore, if the presence of tissue hypoxia is important in 
the development of GI mucosal damage, then we have to go further in the deter-
mination of the direction of the quantities and changes of cellular energy storage 
molecule, namely, “adenosine triphosphate (ATP),” in the healthy and ulcerated 
GI mucosa. However it is also important that the determination of ATP alone is 
possible only with the biochemical markers of the cell reactions. Consequently, 
our attention forwarded to biochemical research profile. Perhaps, it is not needed 
to mention that this is an extremely big challenge for the physicians working in the 
everyday medical practice (as internists).
The measurement of ATP in the different GI mucosal tissues represents only the 
equilibrium between the breakdown of ATP and its resynthesis. The oxygenization 
of mucosal tissues is not necessary in the case of ATP breakdown; however energy 
will be liberated by this biochemical reaction. The liberated energy is necessary 
for the normal functions of the very different cellular events (active transport at 
the cell membrane, secretory responses of the stomach, protein synthesis, etc.). 
However, the ATP resynthesis is possible only in circumstances of well-oxygenized 
tissues; meanwhile if the statement is true that hypoxemic event is present in the 
ulcerated gastrointestinal mucosa, consequently the ATP resynthesis is a priori 
inhibited. We suggested at the start of our biochemical examinations that we will 
find these results in a later time.
We had another (but essential) problem at that time, namely, in patients with 
PUD, we use the drugs in medical treatment; all of them block the active metabolic 
processes at least in the human gastric fundic mucosa (decrease of gastric acid 
secretion). If this statement was absolutely true, then why is the application of 
different drugs inhibiting the gastric acid section useful for the healing of damaged 
mucosal damage? There was a contradiction in objecto.
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From 1964, we started with the biochemical examinations of the stomach in 
animal gastric tissues and in human gastric (fundic, antral, and jejunal) mucosa 
obtained in resecates at human gastric surgery. We did biochemical extractions 
of acid-soluble inorganic and organic phosphates, phospholipid phosphates, 
ribonucleic (RNA), and deoxyribonucleic acid (DNA). These biochemical frac-
tions of gastric tissues generally represented the main components of cells: lipid 
(as membrane), acid-soluble inorganic and organic phosphates (mitochondrion), 
RNA (partly the cytoplasm and well as nucleus), and DNA (nucleus). In other 
words, we tried to study the different compartments of gastrointestinal cells. 
It was important to note that at least 0.3–0.5 g wet tissue sample was necessary 
to carry out of the abovementioned biochemical extractions. Of course, more 
tissue samples were obtained in the different parts of the human stomach, and 
all biochemical extractions and the classical measurements were done at the 
same time. The results were calculated and expressed to 1.0 mg DNA. Classical 
histological examinations were done. The tissue samples from the human gastric 
(antral), duodenal, and jejunal ulcers (after Billroth II operation) were obtained 
from different distances to form the edge of ulcer. In a later phase, we were able 
to successfully prepare membrane-bound ATP-dependent enzymes, namely, the 
Na+-K+−ATPase and adenylate cyclase, directly from the gastric mucosa from 
rats and animals, and we received a possibility to study actions of different drugs 
on both enzymes, firstly in vitro circumstances, later in living organs in animal 
observations (of course). These results were critically summarizing in the last 
years [1–4]. (I used Tables 1, 2 and Figures 1–5, together with the given informa-
tion texts to these demonstrations, and used in the text the reference list number 
used in the original summary monography).
Drugs ATP-ADP transformation ATP-cAMP transformation
Effects Doses (M) Effects Doses (M)
Acetylcholine Stimulation 10−7 M → Inhibition 10−4 M →
Parasympatholytics:
 Atropine Inhibition 10−11 M → Stimulation 10−8 M →
 Isopropamide Inhibition 10−8 M → Stimulation 10−5 M →
 Gastrixon Inhibition 10−8 M → Stimulation 10−4 M →
Epinephrine Inhibition 10−9 M → Stimulation 10−7 M →
β-blocker (Visken) Stimulation 10−4 M → Inhibition 10−5 M →
Histamine Inhibition 10−11 M → Stimulation 10−8 M →
Cimetidine Stimulation(?) 10−4 M → Inhibition 10−6 M →
 Pentagastrin Inhibition 10−11 M → Stimulation 10−9 →
PGE1 Inhibition 10
−11 M → Stimulation 10−9 M →
PGE2 Inhibition 10
−11 M → Stimulation 10−9 M →
Ouabain Inhibition 10−8 M → Stimulation 10−4 M →
cAMP Inhibition 10−13 M →
*Direct effects of the membrane-bound ATP-splitting enzyme activities.
Table 1. 
Pharmacological effects on the transformation of ATP into ADP by membrane ATPase and the ATP-cAMP 
transformation by adenylate cyclase from rat and human gastric, fundic, antral, duodenal, and jejunal 
mucosae [113]* (with kind permission).
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Figure 1. 
Biochemically regulatory pathways between Na+-K+-dependent ATPase and tissue levels of ATP and ADP 
in the human gastric fundic mucosa on dependence of gastric BAO values (means ± SEM) [25] (with kind 
permission).
Figure 2. 
Biochemically regulatory pathways between Na+-K+-dependent ATPase and tissue levels of ATP and ADP in 
the human gastric fundic mucosa in dependence of gastric maximal acid output (MAO) values [65] (with kind 
permission).





Ach Stimulation 5.50 1.00Ach 5.50
Histamine Inhibibion 9.70 1.00Ouabain 9.70
Pentagastrin Inhibibion 10.55 0.87Ouabain 10.55
ATP-adenylate cyclase-cAMP
Ach Inhibition 5.30 −0.70Pentagastrin 5.30
Histamine Stimulation 9.30 1.00Pentagastrin 9.30
Pentagastrin Stimulation 9.40 1.00 9.40
Table indicates affinity (pD2) and intrinsic activity (pA2) curves for the actions of acetylcholine, histamine, and 
pentagastrin. This table also indicates the contradictory actions of these agents on Na+-K+-dependent and adenylyl 
cyclase systems.
Table 2. 
Correlations between the magnitudes of drug actions on Na+-K+-dependent ATPase and the magnitudes of 
Na+-K+-ATPase activity prepared from the human gastric fundic mucosa.
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There are some important notes from the clinical researchers and directions of 
basic researchers:
1. These types of biochemical pharmacological studies just are able to give an 
actual information (owing the human ethical positions, therapeutic protocols 
Figure 3. 
Changes in the extents of ATP-ADP transformation in the antral mucosa of patients with chronic antral ulcer 
in the ulcerated and non-ulcerated (control) mucosae (means ± SEM) [127, 145] (with kind permission).
Figure 4. 
Comparative demonstration in the changes of the tissue levels of ATP in the ulcerated vs. non-ulcerated antral, 
duodenal, and jejunal mucosae (the musculature located under the examined mucosa tissues) (means ± SEM) 
[143] (with kind permission).
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used in patients’ medical therapy, human rights). These problems are in the 
case of basic research also.
2. In animal models we really inform the provocation agents (we used 17 differ-
ent models), and we used all the time a dose–response curve and followed the 
time-course events. All the biochemical examinations (from one animal) were 
done at the same time. The results were calculated. The applied agents were 
expressed in molecular weights, and the affinity and intrinsic values (curves) 
were calculated from the obtained dose–response curves.
3. The evaluation of the obtained results was evaluated at that time when the 
whole observations were finished.
4. These types of examination can be very hard work for clinicians.
5. I tried to demonstrate by my works how the clinicians are able to create a 
special bridge between the basic and clinical research works.
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Figure 5. 
The schematic presentation of biochemical buildup of human gastrointestinal mucosa in patients with 
different gastric acid secretory responses. All of the adenine and adenosine compounds increased significantly 
(meanwhile the stream of ATP breakdown enhanced in both directions) in the gastric corpus mucosa in 
comparison to those results obtained in the corpus mucosa of patients with hyperacidity. The same biochemical 
parameters were obtained in the ulcerated antral, duodenal, and jejunal mucosa in patients with chronic 
antral, duodenal, and jejunal mucosae. So the biochemical structure of human chronic antral, duodenal, and 
jejunal mucosa is the same as that obtained in the corpus fundic mucosa in patients with gastric hyperacidity 
[149, 150] (with kind permission).
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